Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Wenzl

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Digestive Diseases and Sciences|November 9, 2014
Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's diseaseHeimo H Wenzl, Christian Primas, Gottfried Novacek, et al.
Zeitschrift Fur Gastroenterologie|June 15, 2006
[Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH]C Dejaco, T Haas, A Kirchgatterer, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|October 14, 2006
[Working hours and job satisfaction among physicians in hospitals and general practice in Munich. Results of an anonymous questionnaire]S Bornschein, B Erbas, S Borelli, et al.
Endoscopy|October 1, 1994
Prevalence of Helicobacter pylori antibodies in the serum of gastroenterologists in AustriaH Pristautz, A Eherer, R Brezinschek, et al.
Digestive Diseases and Sciences|April 29, 1999
Anti-cardiolipin antibodies in patients with inflammatory bowel diseaseB W Aichbichler, W Petritsch, G A Reicht, et al.
Journal of Crohn'S & Colitis|December 3, 2010
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel diseaseW Miehsler, G Novacek, H Wenzl, et al.
Inflammatory Bowel Diseases|August 1, 2013
Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitisPatrizia K Kump, Hans-Peter Gröchenig, Stefan Lackner, et al.
Alimentary Pharmacology & Therapeutics|October 21, 2017
The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitisP Kump, P Wurm, H P Gröchenig, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Digestive Diseases and Sciences|November 9, 2014
Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's diseaseHeimo H Wenzl, Christian Primas, Gottfried Novacek, et al.
Zeitschrift Fur Gastroenterologie|June 15, 2006
[Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH]C Dejaco, T Haas, A Kirchgatterer, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|October 14, 2006
[Working hours and job satisfaction among physicians in hospitals and general practice in Munich. Results of an anonymous questionnaire]S Bornschein, B Erbas, S Borelli, et al.
Endoscopy|October 1, 1994
Prevalence of Helicobacter pylori antibodies in the serum of gastroenterologists in AustriaH Pristautz, A Eherer, R Brezinschek, et al.
Digestive Diseases and Sciences|April 29, 1999
Anti-cardiolipin antibodies in patients with inflammatory bowel diseaseB W Aichbichler, W Petritsch, G A Reicht, et al.
Journal of Crohn'S & Colitis|December 3, 2010
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel diseaseW Miehsler, G Novacek, H Wenzl, et al.
Inflammatory Bowel Diseases|August 1, 2013
Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitisPatrizia K Kump, Hans-Peter Gröchenig, Stefan Lackner, et al.
Alimentary Pharmacology & Therapeutics|October 21, 2017
The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitisP Kump, P Wurm, H P Gröchenig, et al.
Pageof 7